AUG 24, 2021 8:00 AM PDT

A comparison of drugs for relapsing-remitting multiple sclerosis.

WRITTEN BY: J. Bryce Ortiz

Multiple sclerosis (MS) is a rare and unpredictable autoimmune disease in which the body’s innate immune system attacks cells of the nervous system and breaks down the communication between nerve cells. The best current estimates show that nearly 1 million people in the United States are living with MS. The disease course of MS is unpredictable, and the cause is still unknown, but many individuals with MS may live symptom free for most of their lives. However, in some individuals debilitating symptoms may develop which include numbness or weakness of limbs, tremors, vision problems, fatigue, and problems with bowel and bladder function.  

While there is no cure for MS, treatment focuses on modifying the progression of the disease and targets the immune system to prevent nerve damage. And while several disease modifying treatments exists, most patients with MS have a relapsing-remitting disease course. This means that the patient will experience periods of new MS-related symptoms (or relapses) that improve partially or completely for periods of time, and the disease enters a remission phase for months or years. In a recent study published in Frontiers in Neurology, researchers investigated the long-term efficacy of two drugs that are used for patients with highly active relapsing-remitting MS. 

As discussed in the video, Natalizumab has been a treatment for relapsing-remitting MS for the past 16 years. Additionally, fingolimod is another approved treatment for the disease. However, no study has directly compared the two drugs in terms of efficacy in patients after long-term use. In their study, the researchers compared patients who have taken either drug and compared time to disability improvement and time to disability worsening. It was found that the drug Natalizumab was superior to the other drug in terms of relapse to MS symptoms and other markers as determined by brain scans. As such, the drug is more beneficial to MS patients and provides relief from symptoms and improves the lives of patients. 

 

Sources: Mayo ClinicFrontiers in Neurology

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
JUL 13, 2022
Clinical & Molecular DX
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
JUL 13, 2022
Nipah Virus: Moderna Invests in a Vaccine for the Virus that Fauci Calls a 'Pandemic Threat'
In Malaysia in the fall of 1998, a mystery ailment swept through the local pig-farming community, eventually leading to ...
AUG 07, 2022
Neuroscience
Physiotherapy Technique Significantly Improves Chronic Back Pain
AUG 07, 2022
Physiotherapy Technique Significantly Improves Chronic Back Pain
Sensorimotor retraining significantly improves pain intensity in chronic low back pain. The corresponding study was publ ...
SEP 04, 2022
Drug Discovery & Development
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
SEP 04, 2022
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
Brief exposure to rapamycin, a promising anti-aging drug, may have similar effects on health and lifespan as longer trea ...
SEP 11, 2022
Drug Discovery & Development
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
SEP 11, 2022
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
Researchers found that mice more consistently experience antidepressant effects from ketamine when administered by men a ...
SEP 27, 2022
Clinical & Molecular DX
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
SEP 27, 2022
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
In advanced stages of skin cancer, patients develop brain metastases about 90% of the time. Though this is one of the mo ...
SEP 22, 2022
Cannabis Sciences
Study of Regulations and Risks Associated with Growing Recreational and Medical Cannabis Market
SEP 22, 2022
Study of Regulations and Risks Associated with Growing Recreational and Medical Cannabis Market
A study published in Environmental Health Perspectives advises state and federal regulators to assess the health and saf ...
Loading Comments...